中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
10期
38-39,40
,共3页
血栓通%阿托伐他汀%急性冠脉综合征
血栓通%阿託伐他汀%急性冠脈綜閤徵
혈전통%아탁벌타정%급성관맥종합정
Xueshuantong%Atorvastatin%Acute coronary syndrome
目的：探讨血栓通联合阿托伐他汀治疗急性冠脉综合征的临床效果。方法：选取本院2011年4月-2013年4月诊治的急性冠脉综合征患者96例，根据治疗方案分为两组，48例患者采用阿托伐他汀治疗为对照组，48例患者采用血栓通联合阿托伐他汀治疗为观察组，疗程4周，比较两组患者的临床指标、治疗效果、心脑血管事件情况。结果：观察组患者总胆固醇、三酰甘油、低密度脂蛋白胆固醇、C反应蛋白、B型脑钠肽均明显小于对照组，两组比较差异均有统计学意义（P<0.05）；观察组患者高密度脂蛋白胆固醇、总有效率均明显高于对照组，两组比较差异均有统计学意义（P<0.05）；观察组患者心脑血管事件发生率明显低于对照组，两组比较差异均有统计学意义（P<0.05）。结论：血栓通联合阿托伐他汀可明显改善急性冠脉综合征患者的临床指标，提高治愈率，心脑血管事件少且安全性高，值得临床推广使用。
目的：探討血栓通聯閤阿託伐他汀治療急性冠脈綜閤徵的臨床效果。方法：選取本院2011年4月-2013年4月診治的急性冠脈綜閤徵患者96例，根據治療方案分為兩組，48例患者採用阿託伐他汀治療為對照組，48例患者採用血栓通聯閤阿託伐他汀治療為觀察組，療程4週，比較兩組患者的臨床指標、治療效果、心腦血管事件情況。結果：觀察組患者總膽固醇、三酰甘油、低密度脂蛋白膽固醇、C反應蛋白、B型腦鈉肽均明顯小于對照組，兩組比較差異均有統計學意義（P<0.05）；觀察組患者高密度脂蛋白膽固醇、總有效率均明顯高于對照組，兩組比較差異均有統計學意義（P<0.05）；觀察組患者心腦血管事件髮生率明顯低于對照組，兩組比較差異均有統計學意義（P<0.05）。結論：血栓通聯閤阿託伐他汀可明顯改善急性冠脈綜閤徵患者的臨床指標，提高治愈率，心腦血管事件少且安全性高，值得臨床推廣使用。
목적：탐토혈전통연합아탁벌타정치료급성관맥종합정적림상효과。방법：선취본원2011년4월-2013년4월진치적급성관맥종합정환자96례，근거치료방안분위량조，48례환자채용아탁벌타정치료위대조조，48례환자채용혈전통연합아탁벌타정치료위관찰조，료정4주，비교량조환자적림상지표、치료효과、심뇌혈관사건정황。결과：관찰조환자총담고순、삼선감유、저밀도지단백담고순、C반응단백、B형뇌납태균명현소우대조조，량조비교차이균유통계학의의（P<0.05）；관찰조환자고밀도지단백담고순、총유효솔균명현고우대조조，량조비교차이균유통계학의의（P<0.05）；관찰조환자심뇌혈관사건발생솔명현저우대조조，량조비교차이균유통계학의의（P<0.05）。결론：혈전통연합아탁벌타정가명현개선급성관맥종합정환자적림상지표，제고치유솔，심뇌혈관사건소차안전성고，치득림상추엄사용。
Objective:To investigate the clinical effect of xueshuantong combined with atorvastatin in treatment of acute coronary syndrome. Method:Ninety-six patients with acute coronary syndrome were selected in hospital from April 2011 to April 2013. According to treatment,patients were divided into two groups. Forty-eight patients treated by atorvastatin as control group. Forty-eight patients treated by xueshuantong combined with atorvastatin as observation group. Course of treatment was 4 weeks. Clinical parameters,treatment effect,cardiovascular cerebrovascular events were compared between two groups. Result:Total cholesterol,triglycerides,LDL cholesterol,C-reactive protein,B-type natriuretic peptide of observation group were significantly less than those of the control group,and the differences between the two groups were all statistically significant(P<0.05). HDL cholesterol,total effective rate in observation group were significantly higher than those of the control group,and the difference between the two groups were all statistically significant(P<0.05). Incidence of cardiovascular cerebrovascular events of observation group was significantly lower than that of control group,and the difference between the two groups was all statistically significant(P<0.05). Conclusion:Xueshuantong combined with atorvastatin can significantly improve clinical parameters of patients with acute coronary syndrome,which can also improve cure rate. Xueshuantong combined with atorvastatin have fewer cardiovascular cerebrovascular events and high safety,which is worthy of clinical use.
